MedTrace Logo

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

NCT03986970 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-08-02

No results posted yet for this study

Summary

To compare the effect of different PrEP drugs (FTC-TDF and FTC-TAF), doses and timing of doses on p24 antigen level in resected foreskin tissue following HIV exposure ex vivo challenge.

Conditions

Interventions

DRUG

Tenofovir

Pre-exposure prophylaxis

Sponsors & Collaborators

  • University of Cape Town

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • MRC/UVRI Uganda Research Unit

    collaborator UNKNOWN

  • Karolinska Institutet

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • Wits Health Consortium (Pty) Ltd

    lead OTHER

Principal Investigators

  • Neil A Martinson · Perinatal HIV Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
24 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2021-02-25
Completion
2021-02-25

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986970 on ClinicalTrials.gov